The content on this site is intended for healthcare professionals only
Dr Mariana Chavez MacGregor speaks to ecancer at the ASCO Direct Highlights 2022 Miami Symposium about some of the latest updates in the field of hormone receptor positive HER2 negative breast cancer from this year's ASCO annual meeting.
She first highlights the DESTINY-Breast04 trial, which focuses on the use of trastuzumab deruxtecan in patients that are HER2 1 or 2 plus, believing that the results are practice changing.
Dr Chavez MacGregor also covers more studies from the metastatic setting including the MAINTAIN trial and also trials in the early stage setting.
Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient
Transforming cancer care in India: The Access Cancer Care Initiative
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Choosing Wisely for young women with breast cancer: Radiotherapy
Choosing Wisely in endometrial & cervix cancers: Medical therapy
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications
African oncologists interaction with pharmaceutical industry
The role of lymph nodes in stage 3 lung cancer
